VDAC1 and Hepatic steatosis: Our research suggested that SA (30 mg/kg) protected the liver mitochondrial structure and function by targeting the mitochondrial/VDAC1 Pathway, suggesting that VDAC1 inhibition might contribute to SA-mediated mitochondrial protection in mice with HFD-induced hepatic steatosis (Le et al., 2018).